← Analyst Upside
AU · rank #17 · 2026-09-10
IMCD
AMSTERDAM · EUR · $6.77B (USD)
SignalBuy1.3strength 1.3 / 10
verdict · PROCEED
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 0.732 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.09 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 8 |
| Insider signal (90d) | — |
| Analyst upside Consensus target $117.36 | +20.0% |
| Momentum acceleration 3-month minus 12-month momentum. | +8.39% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.29 |
| Gross margin TTM | +25.0% |
| 52w high | $103.20 |
| Market cap (USD) | $6.77B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
IMCD NV is a leading global distributor and formulator of specialty chemicals and ingredients, serving diversified industrial and life sciences end markets.
Rationale
High analyst consensus and 20% upside potential are validated by IMCD's robust Q2 2026 organic recovery and positive earnings revisions following resilient H1 cash EPS growth.
Material risks
- 1Margin dilution and integration issues from structurally lower-margin acquisitions, which compressed the gross margin by 0.7 percentage points to 24.9% in H1 2026.
- 2Exposure to industrial cycle volatility and sector-wide softness, particularly across European end markets.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.
OpenAI
Proceed
Claude
Caution
Gemini
Proceed